{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T21:34:53Z","timestamp":1773264893434,"version":"3.50.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T00:00:00Z","timestamp":1755648000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T00:00:00Z","timestamp":1755648000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Hainan Province Natural Science Foundation Project","award":["No. 820MS128"],"award-info":[{"award-number":["No. 820MS128"]}]},{"name":"Hainan Provincial Clinical Medical Center Construction Project Funding","award":["Document No. Qiong Wei Yi Han (2021) 75"],"award-info":[{"award-number":["Document No. Qiong Wei Yi Han (2021) 75"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Med Res"],"DOI":"10.1186\/s40001-025-02938-0","type":"journal-article","created":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T06:01:00Z","timestamp":1755669660000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Serum LACC1 level is a predictor of response to upadacitinib treatment in patients with rheumatoid arthritis: a prospective observational cohort study"],"prefix":"10.1186","volume":"30","author":[{"given":"Zhou","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"YuWei","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ShuDian","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,20]]},"reference":[{"key":"2938_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/nu13103506","author":"T Raad","year":"2021","unstructured":"Raad T, Griffin A, George ES, et al. Dietary interventions with or without omega-3 supplementation for the management of rheumatoid arthritis: a systematic review. Nutrients. 2021. https:\/\/doi.org\/10.3390\/nu13103506.","journal-title":"Nutrients"},{"issue":"2","key":"2938_CR2","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.immuni.2017.02.006","volume":"46","author":"GS Firestein","year":"2017","unstructured":"Firestein GS, McInnes IB. Immunopathogenesis of rheumatoid arthritis. Immunity. 2017;46(2):183\u201396 (PMID: 28228278).","journal-title":"Immunity"},{"issue":"2","key":"2938_CR3","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.bj.2020.06.010","volume":"44","author":"MI Edilova","year":"2021","unstructured":"Edilova MI, Akram A, Abdul-Sater AA. Innate immunity drives pathogenesis of rheumatoid arthritis. Biomed J. 2021;44(2):172\u201382 (PMID: 32798211).","journal-title":"Biomed J"},{"key":"2938_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23020905","author":"S Jang","year":"2022","unstructured":"Jang S, Kwon EJ, Lee JJ. Rheumatoid arthritis: pathogenic roles of diverse immune cells. Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms23020905.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"2938_CR5","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1080\/13543784.2023.2199919","volume":"32","author":"S Kubo","year":"2023","unstructured":"Kubo S, Nakayamada S, Tanaka Y. JAK inhibitors for rheumatoid arthritis. Expert Opin Investig Drugs. 2023;32(4):333\u201344 (PMID: 37014106).","journal-title":"Expert Opin Investig Drugs"},{"issue":"5","key":"2938_CR6","doi-asserted-by":"publisher","first-page":"688","DOI":"10.25259\/IJDVL_8_2023","volume":"89","author":"SP Raychaudhuri","year":"2023","unstructured":"Raychaudhuri SP, Raychaudhuri SK. JAK inhibitor: Introduction. Indian J Dermatol Venereol Leprol. 2023;89(5):688\u201390 (PMID: 37609754).","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"7","key":"2938_CR7","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1136\/annrheumdis-2020-219012","volume":"80","author":"PG Traves","year":"2021","unstructured":"Traves PG, Murray B, Campigotto F, Galien R, Meng A, Di Paolo JA. JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib. Ann Rheum Dis. 2021;80(7):865\u201375 (PMID: 33741556).","journal-title":"Ann Rheum Dis"},{"key":"2938_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2022.120516","volume":"298","author":"S Srivastava","year":"2022","unstructured":"Srivastava S, Rasool M. Underpinning IL-6 biology and emphasizing selective JAK blockade as the potential alternate therapeutic intervention for rheumatoid arthritis. Life Sci. 2022;298: 120516 (PMID: 35367240).","journal-title":"Life Sci"},{"issue":"5","key":"2938_CR9","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1007\/s10067-023-06513-y","volume":"42","author":"AM Kakehasi","year":"2023","unstructured":"Kakehasi AM, Radominski SC, Baravalle MD, et al. Safety of upadacitinib in Latin American patients with rheumatoid arthritis: an integrated safety analysis of the SELECT phase 3 clinical program. Clin Rheumatol. 2023;42(5):1249\u201358 (PMID: 36715850).","journal-title":"Clin Rheumatol"},{"issue":"10188","key":"2938_CR10","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1016\/S0140-6736(19)30419-2","volume":"393","author":"JS Smolen","year":"2019","unstructured":"Smolen JS, Pangan AL, Emery P, et al. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study. Lancet. 2019;393(10188):2303\u201311 (PMID: 31130260).","journal-title":"Lancet"},{"issue":"11","key":"2938_CR11","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1358\/dot.2020.56.11.3191007","volume":"56","author":"P Stamatis","year":"2020","unstructured":"Stamatis P, Bogdanos DP, Sakkas LI. Upadacitinib tartrate in rheumatoid arthritis. Drugs Today (Barc). 2020;56(11):723\u201332 (PMID: 33332480).","journal-title":"Drugs Today (Barc)"},{"key":"2938_CR12","doi-asserted-by":"crossref","unstructured":"Sanmarti R, Corominas H. Upadacitinib for patients with rheumatoid arthritis: a comprehensive review. J Clin Med. 2023;12(5). PMID: 36902522.","DOI":"10.3390\/jcm12051734"},{"issue":"8","key":"2938_CR13","volume":"16","author":"MA Ramirez Huaranga","year":"2024","unstructured":"Ramirez Huaranga MA, Calvo Pascual LA, Velasco Sanchez D, et al. Real-world experience with janus kinase inhibitors in immune-mediated diseases: clinical experience of a university hospital. Cureus. 2024;16(8): e67729 (PMID: 39318929).","journal-title":"Cureus"},{"issue":"1","key":"2938_CR14","doi-asserted-by":"publisher","first-page":"183","DOI":"10.4049\/jimmunol.1800636","volume":"202","author":"C Skon-Hegg","year":"2019","unstructured":"Skon-Hegg C, Zhang J, Wu X, et al. LACC1 regulates TNF and IL-17 in mouse models of arthritis and inflammation. J Immunol. 2019;202(1):183\u201393 (PMID: 30510070).","journal-title":"J Immunol"},{"issue":"2","key":"2938_CR15","first-page":"207","volume":"82","author":"J Jiao","year":"2022","unstructured":"Jiao J, Tian S, Bao J, Wang Z, Xie X, Yang G. LACC1 contributes to inflammation and cognitive disorder after stroke via the AMPK\/NLRP3 pathway. Acta Neurobiol Exp (Wars). 2022;82(2):207\u201312.","journal-title":"Acta Neurobiol Exp (Wars)"},{"issue":"4","key":"2938_CR16","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/gene.2016.17","volume":"17","author":"G Assadi","year":"2016","unstructured":"Assadi G, Saleh R, Hadizadeh F, et al. LACC1 polymorphisms in inflammatory bowel disease and juvenile idiopathic arthritis. Genes Immun. 2016;17(4):261\u20134 (PMID: 27098602).","journal-title":"Genes Immun"},{"key":"2938_CR17","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20201006","author":"O Omarjee","year":"2021","unstructured":"Omarjee O, Mathieu AL, Quiniou G, et al. LACC1 deficiency links juvenile arthritis with autophagy and metabolism in macrophages. J Exp Med. 2021. https:\/\/doi.org\/10.1084\/jem.20201006.","journal-title":"J Exp Med"},{"issue":"13","key":"2938_CR18","doi-asserted-by":"publisher","first-page":"4525","DOI":"10.1016\/j.celrep.2019.11.105","volume":"29","author":"C Huang","year":"2019","unstructured":"Huang C, Hedl M, Ranjan K, Abraham C. LACC1 required for NOD2-induced, ER stress-mediated innate immune outcomes in human macrophages and LACC1 risk variants modulate these outcomes. Cell Rep. 2019;29(13):4525\u201339.","journal-title":"Cell Rep"},{"issue":"1","key":"2938_CR19","doi-asserted-by":"publisher","first-page":"45","DOI":"10.4196\/kjpp.24.079","volume":"29","author":"M Xin","year":"2025","unstructured":"Xin M, Jin H, Guo X, et al. Retinoic acid ameliorates rheumatoid arthritis by attenuating inflammation and modulating macrophage polarization through MKP-1\/MAPK signaling pathway. Korean J Physiol Pharmacol. 2025;29(1):45\u201356 (PMID: 39539171).","journal-title":"Korean J Physiol Pharmacol"},{"issue":"5","key":"2938_CR20","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1097\/BOR.0000000000000637","volume":"31","author":"PA Nigrovic","year":"2019","unstructured":"Nigrovic PA, Martinez-Bonet M, Thompson SD. Implications of juvenile idiopathic arthritis genetic risk variants for disease pathogenesis and classification. Curr Opin Rheumatol. 2019;31(5):401\u201310.","journal-title":"Curr Opin Rheumatol"},{"issue":"2","key":"2938_CR21","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/BF02912911","volume":"21","author":"AN Rao","year":"2006","unstructured":"Rao AN, Shetty BV, Vasudevan DM. Positive influence of methotrexate-hydroxychloroquine combination on the expression of GM-CSF receptor on neutrophils of synovial fluid in rheumatoid arthritis. Indian J Clin Biochem. 2006;21(2):49\u201352 (PMID: 23105613).","journal-title":"Indian J Clin Biochem"},{"issue":"12","key":"2938_CR22","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1136\/annrheumdis-2018-214918","volume":"78","author":"D Aletaha","year":"2019","unstructured":"Aletaha D, Maa JF, Chen S, et al. Effect of disease duration and prior disease-modifying antirheumatic drug use on treatment outcomes in patients with rheumatoid arthritis. Ann Rheum Dis. 2019;78(12):1609\u201315.","journal-title":"Ann Rheum Dis"}],"container-title":["European Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-025-02938-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40001-025-02938-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-025-02938-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T17:43:56Z","timestamp":1757439836000},"score":1,"resource":{"primary":{"URL":"https:\/\/eurjmedres.biomedcentral.com\/articles\/10.1186\/s40001-025-02938-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,20]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2938"],"URL":"https:\/\/doi.org\/10.1186\/s40001-025-02938-0","relation":{},"ISSN":["2047-783X"],"issn-type":[{"value":"2047-783X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,20]]},"assertion":[{"value":"16 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.\u00a0All subjects were approved by Hainan General Hospital (No. 2021-233).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"779"}}